According to the Zhitong Finance App, Shiyao Group (01093.HK) announced that the recombinant respiratory syncytial virus (RSV) vaccine (SYS6057) developed by the Group has been approved by the China Drug Administration and can conduct clinical trials in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.